BioSpace News Archive

Dr. Reddy’s Laboratories Ltd. announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration.

The global SDS poly acrylamide gel electrophoresis market is driven primarily by advancements in the field of molecular biology.

The North America unit dose manufacturing market is expected to rise at a noticeable speed in the upcoming years.

Oral inhalation devices are used to prevent difficulty while breathing, coughing, wheezing, and others such that the patient or person can feel relieved after using the oral inhalation devices to inhale different drugs.

Changing regulatory scene, expanding interest for the quicker endorsement measure, and financial and serious tensions are a portion of the key variables expected to drive the market.

Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug application (IND) to initiate a first-in-human clinical trial of OCU400 (AAV-NR2E3), a modifier gene therapy candidate for the treatment of retinitis pigmentosa resulting from genetic mutations found in NR2E3 and Rhodopsin.

Oncology Pharma Inc. are pleased to give a year end update and provide an outlook for what to look for in the coming months and year ahead.

Aligos Therapeutics, Inc. today announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 (NCT05090111).

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, issued the following statement to stockholders.

Clover Biopharmaceuticals, Ltd. and Ascentage Pharma announced that they have entered into a clinical collaboration to evaluate Clover’s SCB-313, a recombinant human TRAIL-Trimer fusion protein and Ascentage Pharma’s APG-1387, a second mitochondria-derived activator of caspase -mimetic/inhibitor of apoptosis proteins antagonist, in a Phase 1b/2 clinical trial for advanced peritoneal carcinomatosis.